Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 172

1.

Development and validation of the AML-QOL: a quality of life instrument for patients with acute myeloid leukemia.

Buckley SA, Halpern AB, Othus M, Jimenez-Sahagun D, Walter RB, Lee SJ.

Leuk Lymphoma. 2020 Jan 7:1-10. doi: 10.1080/10428194.2019.1709838. [Epub ahead of print]

PMID:
31909637
2.

Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease.

Morsink LM, Bezerra ED, Othus M, Wood BL, Fang M, Sandmaier BM, Mielcarek MB, Deeg HJ, Schoch G, Appelbaum FR, Walter RB.

Leukemia. 2019 Dec 3. doi: 10.1038/s41375-019-0671-x. [Epub ahead of print] No abstract available.

PMID:
31796913
3.

Trillions and Trillions: Herpes Simplex Virus-1 Hepatitis in an Immunocompetent Adult.

Ikuta K, Roychoudhury P, Xie H, Mcclurkan CL, Walkiewicz M, Makhsous N, Huang ML, Beru Y, Alam M, Shepherd A, Lamotte ED, Patel K, Morris A, Ҫoruh B, Yu L, Bhattacharya R, Cheng R, Walter RB, Limaye AP, Lockwood CM, Holland SM, Rakita RM, Koelle DM, Greninger AL.

Open Forum Infect Dis. 2019 Nov 5;6(11):ofz465. doi: 10.1093/ofid/ofz465. eCollection 2019 Nov.

4.

Need for routine examination of left ventricular ejection fraction in patients with AML.

Khan HM, Gardner KM, Shaw C, Halpern AB, Huebner EM, Percival MM, Mirahsani S, Sorror ML, Becker PS, Walter RB, Estey EH.

Leukemia. 2019 Nov 12. doi: 10.1038/s41375-019-0637-z. [Epub ahead of print] No abstract available.

PMID:
31719680
5.

Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia.

Hoffmann AP, Besch AL, Othus M, Morsink LM, Wood BL, Mielcarek M, Estey EH, Appelbaum FR, Walter RB.

Bone Marrow Transplant. 2019 Nov 4. doi: 10.1038/s41409-019-0739-2. [Epub ahead of print] No abstract available.

PMID:
31685932
6.

Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation.

Othus M, Gale RP, Hourigan CS, Walter RB.

Bone Marrow Transplant. 2019 Oct 30. doi: 10.1038/s41409-019-0729-4. [Epub ahead of print]

PMID:
31666655
7.

Independent Associations Between Glomerular Filtration Rate and Serum Bilirubin Level and Early Mortality in Acute Myeloid Leukemia.

Bezerra ED, Othus M, Shawn C, Percival ME, Gardner K, Walter RB, Becker PS, Hendrie PC, Estey EH.

Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):e633-e635. doi: 10.1016/j.clml.2019.06.014. Epub 2019 Aug 1. No abstract available.

PMID:
31648955
8.

Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm.

Halpern AB, Howard NP, Othus M, Hendrie PC, Baclig NV, Buckley SA, Percival MM, Becker PS, Scott BL, Oehler VG, Gernsheimer TB, Keel SB, Orozco JJ, Cassaday RD, Shustov AR, Hartley GA, Welch VL, Estey EH, Walter RB.

Leukemia. 2019 Oct 4. doi: 10.1038/s41375-019-0586-6. [Epub ahead of print] No abstract available.

PMID:
31586148
9.

Novel monoclonal antibody-based therapies for acute myeloid leukemia.

Morsink LM, Walter RB.

Best Pract Res Clin Haematol. 2019 Jun;32(2):116-126. doi: 10.1016/j.beha.2019.05.002. Epub 2019 May 9. Review.

PMID:
31203993
10.

Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?

Vaughn JE, Shankaran V, Walter RB.

Curr Hematol Malig Rep. 2019 Jun;14(3):171-178. doi: 10.1007/s11899-019-00510-2. Review.

PMID:
31079354
11.

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study.

Kayser S, Hills RK, Luskin MR, Brunner AM, Terré C, Westermann J, Menghrajani K, Shaw C, Baer MR, Elliott MA, Perl AE, Ráčil Z, Mayer J, Zak P, Szotkowski T, de Botton S, Grimwade D, Mayer K, Walter RB, Krämer A, Burnett AK, Ho AD, Platzbecker U, Thiede C, Ehninger G, Stone RM, Röllig C, Tallman MS, Estey EH, Müller-Tidow C, Russell NH, Schlenk RF, Levis MJ.

Haematologica. 2020 Jan;105(1):161-169. doi: 10.3324/haematol.2018.208678. Epub 2019 Apr 19.

12.

A real-world, cross-sectional, community survey of symptoms and health-related quality of life of adults with acute myeloid leukemia.

Mamolo CM, Cappelleri JC, Hoang CJ, Kim R, Hadfield A, Middleton C, Rider A, Walter RB.

Future Oncol. 2019 Jun;15(16):1895-1909. doi: 10.2217/fon-2018-0842. Epub 2019 Mar 26.

PMID:
30912462
13.

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.

Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T, Fakouhi KM, Humerickhouse R, Hong WJ, Hayslip J, Roboz GJ.

J Clin Oncol. 2019 May 20;37(15):1277-1284. doi: 10.1200/JCO.18.01600. Epub 2019 Mar 20.

PMID:
30892988
14.

Diagnostic utility of bronchoscopy in adults with acute myeloid leukemia and other high-grade myeloid neoplasms.

Buckley SA, Mark NM, Othus M, Estey EH, Patel K, Walter RB.

Leuk Lymphoma. 2019 Sep;60(9):2304-2307. doi: 10.1080/10428194.2019.1581933. Epub 2019 Mar 11. No abstract available.

PMID:
30856024
15.

Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission.

Godwin CD, Fromm JR, Othus M, Sandmaier BM, Mielcarek MB, Wood BL, Appelbaum FR, Storb R, Walter RB.

Bone Marrow Transplant. 2019 Sep;54(9):1511-1514. doi: 10.1038/s41409-019-0481-9. Epub 2019 Feb 25. No abstract available.

PMID:
30804488
16.

In the Eye of the Beholder: A Conjunctival Lesion in a Woman With Acute Myelogenous Leukemia.

McGuffin SA, Bharadwaj R, Gonzalez-Cuyar LF, Schiffer JT, Stacey AW, Walter RB, Duke ER.

Clin Infect Dis. 2019 Jan 18;68(3):525-529. doi: 10.1093/cid/ciy394. No abstract available.

17.

Outpatient induction and consolidation care strategies in acute myeloid leukemia.

Halpern AB, Walter RB, Estey EH.

Curr Opin Hematol. 2019 Mar;26(2):65-70. doi: 10.1097/MOH.0000000000000481.

PMID:
30585894
18.

CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia.

Halpern AB, Walter RB.

Oncotarget. 2018 Nov 27;9(93):36543-36544. doi: 10.18632/oncotarget.26383. eCollection 2018 Nov 27. No abstract available.

19.

Refining AML outcome prediction.

Hourigan CS, Gale RP, Walter RB.

Leukemia. 2019 Feb;33(2):283-284. doi: 10.1038/s41375-018-0317-4. Epub 2018 Dec 14. No abstract available.

PMID:
30552400
20.

Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Hendrie PC, Percival MM, Becker PS, Smith HA, Oehler VG, Orozco JJ, Cassaday RD, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Estey EH, Walter RB.

Haematologica. 2019 Apr;104(4):e143-e146. doi: 10.3324/haematol.2018.204792. Epub 2018 Nov 8. No abstract available.

Supplemental Content

Loading ...
Support Center